Tiffany A Traina

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Triple-negative breast cancer: adjuvant therapeutic options
    Ayca Gucalp
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10065, USA
    Chemother Res Pract 2011:696208. 2011
  2. ncbi request reprint Aromatase inhibitors for hormonal therapy of early-stage breast cancer
    Tiffany A Traina
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Medicine Service, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Investig Drugs 5:605-10. 2004
  3. ncbi request reprint Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 11:1070-1. 2006
  4. ncbi request reprint Bevacizumab for advanced breast cancer
    Tiffany A Traina
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:303-19. 2007
  5. doi request reprint Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1797-802. 2008
  6. pmc Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling
    Tiffany A Traina
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast Dis 31:7-18. 2010
  7. ncbi request reprint Bevacizumab in the treatment of metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncology (Williston Park) 23:327-32. 2009
  8. doi request reprint Determinants of outcome in elderly patients with positive sentinel lymph nodes
    Amer K Karam
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Evelyn H Lauder Breast Center, New York, NY 10065, USA
    Am J Surg 201:734-40. 2011
  9. doi request reprint Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 131:111-6. 2012
  10. doi request reprint Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer
    Matthew S Pugliese
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:1063-8. 2010

Detail Information

Publications22

  1. pmc Triple-negative breast cancer: adjuvant therapeutic options
    Ayca Gucalp
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10065, USA
    Chemother Res Pract 2011:696208. 2011
    ..In addition, we will examine the available data for the use of cytotoxic chemotherapy in the treatment of TNBC in both the neoadjuvant and adjuvant setting and explore the ongoing development of newer targeted agents...
  2. ncbi request reprint Aromatase inhibitors for hormonal therapy of early-stage breast cancer
    Tiffany A Traina
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Medicine Service, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Investig Drugs 5:605-10. 2004
    ..This review focuses on data on aromatase inhibitors in the adjuvant setting and looks to the future potential of these drugs in both ductal carcinoma in situ and chemoprevention...
  3. ncbi request reprint Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 11:1070-1. 2006
  4. ncbi request reprint Bevacizumab for advanced breast cancer
    Tiffany A Traina
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:303-19. 2007
    ..In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer...
  5. doi request reprint Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1797-802. 2008
    ....
  6. pmc Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling
    Tiffany A Traina
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast Dis 31:7-18. 2010
    ..to hasten and improve anticancer drug development, we created a novel approach to generating and analyzing preclinical dose-scheduling data so as to optimize benefit-to-toxicity ratios...
  7. ncbi request reprint Bevacizumab in the treatment of metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncology (Williston Park) 23:327-32. 2009
    ..In this paper, the clinical trials establishing bevacizumab use for the treatment of breast cancer are reviewed...
  8. doi request reprint Determinants of outcome in elderly patients with positive sentinel lymph nodes
    Amer K Karam
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Evelyn H Lauder Breast Center, New York, NY 10065, USA
    Am J Surg 201:734-40. 2011
    ..Older women are less likely to receive standard of care treatment for breast cancer...
  9. doi request reprint Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 131:111-6. 2012
    ..Capecitabine 7-7 with lapatinib was well tolerated with minimal gastrointestinal toxicity. Antitumor activity was observed in patients with trastuzumab-refractory MBC...
  10. doi request reprint Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer
    Matthew S Pugliese
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:1063-8. 2010
    ..The goal of this study was to examine factors associated with ALND in IHC-only patients...
  11. doi request reprint Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:4125-31. 2011
    ..Bevacizumab has demonstrated the ability to improve outcomes when it is added to chemotherapy, including capecitabine, in the first-line and second-line settings...
  12. doi request reprint Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:628-33. 2010
    ..We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)...
  13. doi request reprint Bevacizumab for advanced breast cancer
    Shari B Goldfarb
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Womens Health (Lond Engl) 6:17-25. 2010
    ..This review article discusses the clinical trials establishing the use of bevacizumab for the treatment of advanced breast cancer...
  14. doi request reprint Triple-negative breast cancer: role of the androgen receptor
    Ayca Gucalp
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
    Cancer J 16:62-5. 2010
    ..Herein, we review the role of the AR in breast cancer tumorigenesis and current progress and future directions in the development of AR-targeted therapies...
  15. pmc Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
    Ayca Gucalp
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 11:306-11. 2011
    ..We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC)...
  16. doi request reprint Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis
    Carmen A Perez
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast Cancer Res Treat 139:497-506. 2013
    ..Black women with TNBC had equivalent local control, but higher risk of regional nodal failure, compared with non-black counterparts. The routine use of comprehensive nodal irradiation may be beneficial for black women with TNBC...
  17. doi request reprint PIK3CA mutation associates with improved outcome in breast cancer
    Kevin Kalinsky
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:5049-59. 2009
    ..The prognostic implication of these activating mutations remains uncertain as moderately sized studies have yielded variable outcomes. Our aim was to determine the prognostic implications of PIK3CA mutations in breast cancer...
  18. doi request reprint The role of the androgen receptor in triple-negative breast cancer
    Payal D Shah
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Womens Health (Lond Engl) 9:351-60. 2013
    ....
  19. doi request reprint Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes
    Amer K Karam
    Department of Surgery, Breast Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 16:1952-8. 2009
    ..We sought to determine the sociodemographic, pathologic, and therapeutic variables that were associated with CALND...
  20. doi request reprint Advances in molecular and clinical subtyping of breast cancer and their implications for therapy
    Karen A Cadoo
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Surg Oncol Clin N Am 22:823-40. 2013
    ..We review the molecular drivers of each subtype and discuss implications for prognosis, clinical management, and future directions. ..
  21. ncbi request reprint Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature
    Tiffany A Traina
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 95:235-41. 2004
    ..We have included a review of the literature of weekly topotecan in the treatment of patients with gynecologic cancer...
  22. ncbi request reprint NCCN Task Force Report: breast cancer in the older woman
    Robert W Carlson
    J Natl Compr Canc Netw 6:S1-25; quiz S26-7. 2008
    ....